Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia.
Fasano
A
A
Istituto di Neurologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Bentivoglio
A R
AR
Ialongo
T
T
Soleti
F
F
Evoli
A
A
D020434:Abducens Nerve Diseases / Q000209:etiology / Q000503:physiopathology; D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D002800:Cholinesterase Inhibitors / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004948:Esotropia / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007273:Injections, Intramuscular; D009157:Myasthenia Gravis / Q000150:complications* / Q000188:drug therapy; D009334:Neck Muscles / Q000187:drug effects* / Q000503:physiopathology; D009801:Oculomotor Muscles / Q000187:drug effects / Q000503:physiopathology; D055502:Secondary Prevention; D014103:Torticollis / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D007166:Immunosuppressive Agents; D019274:Botulinum Toxins, Type A